Current and Future Treatments of Rhinitis and Sinusitis

Gayatri B. Patel, Robert C. Kern, Jonathan A. Bernstein, Park Hae-Sim, Anju T. Peters*

*Corresponding author for this work

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Advances in understanding the pathogenic mechanisms of both rhinitis and chronic rhinosinusitis have resulted in new treatment options, especially for chronic rhinosinusitis. A review of relevant medical and surgical clinical studies shows that intranasal corticosteroids, antihistamines, and allergen immunotherapy continue to be the best treatments for chronic rhinitis. Dupilumab is the first biologic approved for chronic rhinosinusitis with polyps. Omalizumab, mepolizumab, and benralizumab may have a future role in the treatment of chronic rhinosinusitis. Novel corticosteroid delivery devices such as an exhalation delivery system for fluticasone and bioabsorbable sinus implants provide enhanced and localized distribution of corticosteroids. Surgical management tailored to the underlying disease process improves clinical outcomes in chronic rhinosinusitis with or without nasal polyposis. Advances in the understanding of the heterogeneous nature of rhinitis and rhinosinusitis have resulted in more precise treatments. Improving the understanding of different endotypes should provide better knowledge to determine appropriate current and new therapies to treat these diseases.

Original languageEnglish (US)
Pages (from-to)1522-1531
Number of pages10
JournalJournal of Allergy and Clinical Immunology: In Practice
Volume8
Issue number5
DOIs
StatePublished - May 2020

Keywords

  • Bioabsorbable sinus implant
  • Chronic rhinitis
  • Chronic rhinosinusitis
  • Dupilumab
  • EDS-FLU
  • Mepolizumab
  • Nasal polyposis
  • Omalizumab
  • Sinus surgery

ASJC Scopus subject areas

  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Current and Future Treatments of Rhinitis and Sinusitis'. Together they form a unique fingerprint.

  • Cite this